TrialSignal
Clinical trial intelligence report
A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection or Local Ablation (KEYNOTE-937)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03867084
Status
COMPLETED
Phase
Phase 3
Sponsor
Merck Sharp & Dohme LLC
Executive brief
Investment-Ready Snapshot
This clinical trial evaluates the safety and efficacy of pembrolizumab (MK-3475) as adjuvant therapy in patients with HCC who have achieved complete radiological response following surgical resection or local ablation. The study aims to demonstrate superiority in recurrence-free survival (RFS) and overall survival (OS) compared to placebo.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03867084
Indication
Hepatocellular Carcinoma
Modality
monoclonal antibody
Target
Hepatocellular Carcinoma (HCC)
Intervention
Pembrolizumab, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.